Navigation Links
Optimer Pharmaceuticals Announces Lower Recurrence Rates for Fidaxomicin Versus Vancocin(R) in Subgroup Analyses from Its Phase 3 Study for the Treatment of CDI
Date:6/2/2009

ss and concern of CDI among medical professionals and public health officials.

Scheduled Conference Call

The Company will host a conference call for the investment community today beginning at 3:00 p.m. Pacific time (6:00 p.m. Eastern time) to discuss the additional fidaxomicin Phase 3 data and answer questions.

To participate in the live call by telephone, please dial (877) 419-6590 from the U.S., or (719) 325-4893 from outside the U.S. The conference call will be webcast live under the Investors section of Optimer's website at www.optimerpharma.com.

About Fidaxomicin

Fidaxomicin is the first in a new class of antibiotics called macrocyclics, which inhibit the bacterial enzyme RNA polymerase, resulting in the death of Clostridium difficile. The narrow spectrum profile of fidaxomicin may eradicate Clostridium difficile selectively with minimal disruption to the normal intestinal flora. This may facilitate the return of the normal physiological conditions in the colon and reduce the probability of CDI recurrence.

About Optimer Pharmaceuticals

Optimer Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing innovative anti-infective products to treat serious infections and address unmet medical needs. Optimer has two late-stage anti-infective product candidates under development. Fidaxomicin, formerly known as OPT-80, is the only antibiotic therapy currently in Phase 3 worldwide clinical development for Clostridium difficile infection. Prulifloxacin is an antibiotic which has completed two Phase 3 clinical trials for the treatment of travelers' diarrhea, a form of infectious diarrhea. Additional information can be found at http://www.optimerpharma.com.
'/>"/>

SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Optimer Pharmaceuticals Reports First Quarter 2009 Financial Results
2. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
3. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
4. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
5. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
6. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
7. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
8. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
9. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
10. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
11. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2015)... July 24, 2015  Champions Oncology (OTC-BB: CSBR), a ... and services to personalize the development and use of ... and operational results for the fourth quarter and fiscal ... 28, 2015, before market open. The company ... that day at 9:00 a.m. EDT (6:00 a.m. PDT). ...
(Date:7/24/2015)... -- The global next generation sequencing ... by 2022, growing at an estimated CAGR of 40.1% ... by Grand View Research, Inc. Development of faster, more ... significant reduction in cost of sequencing one base pair. ... of next generation sequencing throughout the forecast period. Revenue ...
(Date:7/23/2015)... LOS ANGELES , July 23, 2015 ImmunoCellular ... plans to report financial results for the second quarter 2015 ... hold a conference call and webcast on that day at ... results and provide a business update. The call will be ...   , , , LIVE CALL: ...
(Date:7/23/2015)... ... July 23, 2015 , ... One hundred years ago ... 1915 National Model Aeroplane Competition, with hopes of winning the Henry S. Villard Trophy. ... centennial. , Participants will have the opportunity to build a Free Flight fantasy club ...
Breaking Biology Technology:Champions Oncology to Announce Fourth Quarter Financial Results on Tuesday, July 28 2Next Generation Sequencing (NGS) Market To Reach $27.8 Billion By 2022: Grand View Research, Inc. 2Next Generation Sequencing (NGS) Market To Reach $27.8 Billion By 2022: Grand View Research, Inc. 3Next Generation Sequencing (NGS) Market To Reach $27.8 Billion By 2022: Grand View Research, Inc. 4Next Generation Sequencing (NGS) Market To Reach $27.8 Billion By 2022: Grand View Research, Inc. 5ImmunoCellular Therapeutics to Report Second Quarter 2015 Financial Results on August 6, 2015 2Academy of Model Aeronautics to Start Online Fantasy Flight Competition 2
... NEW YORK, August 28 XTL Biopharmaceuticals,Ltd. (NASDAQ: ... biopharmaceutical company,engaged in the acquisition, development and commercialization ... particularly,neuropathic pain and hepatitis C, today announced that ... Company,s depositary bank,The Bank of New York, will ...
... PARIS, August 28 ExonHit Therapeutics, a drug,and ... discovery,collaboration with Allergan Inc. (NYSE: AGN ), ... reached a success milestone.,As a result of the ... human,clinical testing will be initiated on the first ...
... (Nasdaq:,IDMI) today announced that Jeffrey W. Sherman, M.D., F.A.C.P. ... Senior Vice President,of Research and Development. Dr. Sherman will ... and CEO Timothy P. Walbert. Dr. Sherman brings ... and will lead the regulatory and clinical strategy for ...
Cached Biology Technology:Processing Fees on ADRs to be Waived for two Months 2Processing Fees on ADRs to be Waived for two Months 3ExonHit Therapeutics: Allergan and ExonHit's First Collaboration Compound to Begin Human Clinical Trials 2ExonHit Therapeutics: Allergan and ExonHit's First Collaboration Compound to Begin Human Clinical Trials 3IDM Pharma Names Dr. Jeffrey W. Sherman Chief Medical Officer and Senior Vice President of Research and Development 2IDM Pharma Names Dr. Jeffrey W. Sherman Chief Medical Officer and Senior Vice President of Research and Development 3IDM Pharma Names Dr. Jeffrey W. Sherman Chief Medical Officer and Senior Vice President of Research and Development 4IDM Pharma Names Dr. Jeffrey W. Sherman Chief Medical Officer and Senior Vice President of Research and Development 5
(Date:7/21/2015)... Sweden , July 21, 2015 Today, ... FPC1025. Already received as well as expected revenues in 2015 that ... in FPC,s communicated revenue guidance of approximately 2,200 MSEK for 2015. ... is a leading smartphone manufacturer in China ... selected FPC1 02 5 for Axon ...
(Date:7/21/2015)... , July 21, 2015 Passwords ... as seen in the recent U.S. Office of ... solution to the infosec conundrum, but developers and ... stored. To address this dilemma, Biometrics-as-a-Service provider HYPR ... Biometric Tokenization SDK for third party integration. ...
(Date:7/13/2015)... JOSE, Calif. , July 13, 2015 /PRNewswire/ ... leading developer of human interface solutions, today announced ... generation touch and display driver integration (TDDI) product ... is the first to combine Synaptics , ... with proven display driver technology developed in the ...
Breaking Biology News(10 mins):FPC's Touch Fingerprint Sensor FPC1025 in ZTE's Smartphone Axon 2HYPR Corp. Launches Industry First Biometric Tokenization Platform 2HYPR Corp. Launches Industry First Biometric Tokenization Platform 3HYPR Corp. Launches Industry First Biometric Tokenization Platform 4Synaptics Announces Sampling of Second Generation TDDI Solutions 2Synaptics Announces Sampling of Second Generation TDDI Solutions 3
... The Federation of American Societies for Experimental ... the Science Research Conference (SRC): Glucose transport: Gateway ... Science Research Conference "Glucose transport: Gateway for Metabolic ... role of glucose transport in the control of ...
... of American Societies for Experimental Biology (FASEB) announces ... Conference (SRC): Mitochondrial Assembly and Dynamics in Health, ... Mitochondrial Assembly and Dynamics in Health, Disease and ... where diverse aspects of mitochondrial biology and dysfunction ...
... American Societies for Experimental Biology (FASEB) announces the ... (SRC): Neural Mechanisms in Cardiovascular Regulation. The ... Cardiovascular Regulation, is an important and unique scientific ... regulate normal cardiovascular function, and how dysregulation of ...
Cached Biology News:
PMM2 Immunogen: PMM2 (NP_000294, 47 a.a. ~ 112 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
HOXC11 Antibody...
Rabbit polyclonal to Raf1 ( Abpromise for all tested applications). entrezGeneID: 5894 SwissProtID: P04049...
Sheep polyclonal to hCG beta core fragment ( Abpromise for all tested applications). Antigen: Full length native protein (purified) from human urine. Entrez GeneID: 1082 Swiss Protein ID...
Biology Products: